Affordable Access

deepdyve-link
Publisher Website

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.

Authors
  • de la Torre, Beatriz G1
  • Albericio, Fernando2, 3
  • 1 KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. , (South Africa)
  • 2 School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa. , (South Africa)
  • 3 CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain. , (Spain)
Type
Published Article
Journal
Molecules
Publisher
MDPI AG
Publication Date
Feb 09, 2020
Volume
25
Issue
3
Identifiers
DOI: 10.3390/molecules25030745
PMID: 32050446
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved. Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019. This report analyzes the 48 new drugs of the class of 2019 from a strictly chemical perspective. The classification, which was carried out on the basis of chemical structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small molecules.

Report this publication

Statistics

Seen <100 times